
Paul V. Plourde
Advertisement
Articles by Paul V. Plourde


16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation
ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH, FASCO,Paul V. Plourde,David J. Portman,Senthil Damodaran

Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
New CAR T-Cell Therapy Earns FDA Breakthrough Status in T-Cell Malignancies
2
Median OS Not Yet Reached With New Immunotherapy Combo in 2L Glioblastoma
3
FDA Accepts NDA for Gedatolisib in HR+/HER2–, PIK3CA Wild-Type Breast Cancer
4
FDA Issues Guidance on MRD, CR Outcomes for Multiple Myeloma Approvals
5

